CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
REVENUES:
Net sales	$ 13,680,107	$ 21,886,688	$ 25,949,769
License and royalty revenue	449,685	52,753	23,257
R&D, milestone and grant revenue	3,739,049	2,316,044	1,672,258
TOTAL REVENUES	17,868,841	24,255,485	27,645,284
Cost of product sales	9,417,505	13,768,658	16,831,261
GROSS MARGIN	8,451,336	10,486,827	10,814,023
OPERATING EXPENSES:
Research and development expenses	8,427,554	6,377,839	4,832,537
Selling, general and administrative expenses	7,595,559	7,663,035	7,531,739
TOTAL OPERATING EXPENSES	16,023,113	14,040,874	12,364,276
LOSS FROM OPERATIONS	(7,571,777)	(3,554,047)	(1,550,253)
OTHER INCOME (EXPENSE):
Other expense	0	(4,814)	(5,707)
Interest income	25,548	2,412	5,839
Interest expense	0	(836)	0
TOTAL OTHER INCOME (EXPENSE)	25,548	(3,238)	132
LOSS BEFORE INCOME TAXES (BENEFIT)	(7,546,229)	(3,557,285)	(1,550,121)
Income tax provision (benefit)	5,800,818	(1,160,243)	(412,918)
NET LOSS	$ (13,347,047)	$ (2,397,042)	$ (1,137,203)
Basic loss per share (in dollars per share)	$ (1.26)	$ (0.25)	$ (0.12)
Diluted loss per share (in dollars per share)	$ (1.26)	$ (0.25)	$ (0.12)
Weighted average number of shares outstanding, basic (in shares)	10,622,331	9,626,028	9,530,320
Weighted average number of shares outstanding, diluted (in shares)	10,622,331	9,626,028	9,530,320